Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Mackey

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|November 5, 1999
Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transportersJ R Mackey, S Y Yao, K M Smith, et al.
Leukemia|August 30, 2002
Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case studyT Reiman, K A Graham, J Wong, et al.
Oncogenesis|April 5, 2013
Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobinL Lam, Z Aktary, M Bishay, et al.
Oncogene|January 27, 2010
Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1Z Aktary, K Chapman, L Lam, et al.
Blood|September 6, 2001
Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemiaC M Galmarini, K Graham, X Thomas, et al.
Current Oncology (Toronto, Ont.)|March 5, 2008
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working GroupJ R Mackey, M Clemons, M A Côté, et al.
Cancer Research|October 10, 1998
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell linesJ R Mackey, R S Mani, M Selner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancerJ M Nabholtz, J R Mackey, M Smylie, et al.
Oncology (Williston Park, N.Y.)|August 1, 1997
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancerJ M Nabholtz, M Smylie, J R Mackey, et al.
Oncogene|July 7, 2010
The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanismA C Craik, R A Veldhoen, M Czernick, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|November 5, 1999
Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transportersJ R Mackey, S Y Yao, K M Smith, et al.
Leukemia|August 30, 2002
Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case studyT Reiman, K A Graham, J Wong, et al.
Oncogenesis|April 5, 2013
Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobinL Lam, Z Aktary, M Bishay, et al.
Oncogene|January 27, 2010
Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1Z Aktary, K Chapman, L Lam, et al.
Blood|September 6, 2001
Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemiaC M Galmarini, K Graham, X Thomas, et al.
Current Oncology (Toronto, Ont.)|March 5, 2008
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working GroupJ R Mackey, M Clemons, M A Côté, et al.
Cancer Research|October 10, 1998
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell linesJ R Mackey, R S Mani, M Selner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancerJ M Nabholtz, J R Mackey, M Smylie, et al.
Oncology (Williston Park, N.Y.)|August 1, 1997
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancerJ M Nabholtz, M Smylie, J R Mackey, et al.
Oncogene|July 7, 2010
The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanismA C Craik, R A Veldhoen, M Czernick, et al.
Pageof 6